Positive allosteric modulators

Positive allosteric modulators (PAMs) are a class of drugs that enhance the activity of a receptor in the body by binding to a different site than the primary (orthosteric) site. This binding increases the receptor's response to its natural ligand. PAMs are a focus of drug discovery because they can fine-tune the functioning of a receptor, providing a more nuanced approach than simply blocking or activating it.

Mechanism of Action

PAMs work by binding to allosteric sites, which are distinct from the primary (orthosteric) site where the natural ligand binds. This binding changes the receptor's conformation, or shape, enhancing its response to the natural ligand. This is different from agonists, which bind to the orthosteric site and directly activate the receptor, and antagonists, which bind to the orthosteric site and block the receptor's activation.

Therapeutic Applications

PAMs have potential therapeutic applications in a variety of areas. For example, they are being investigated for use in treating neurological disorders, such as Alzheimer's disease and schizophrenia, because they can enhance the activity of neurotransmitter receptors in the brain. They are also being studied for use in treating cardiovascular diseases, cancer, and inflammatory diseases.

Examples

Examples of PAMs include benzodiazepines, which enhance the activity of the GABA-A receptor, and glutamate receptor modulators, which enhance the activity of the NMDA receptor. Other examples include mGluR5 modulators, which are being investigated for use in treating neurological disorders, and CXCR4 modulators, which are being studied for use in treating cancer.

Challenges and Future Directions

While PAMs hold promise, there are challenges in developing them as drugs. One challenge is that they can lead to overactivation of the receptor, potentially causing side effects. Another challenge is that they can be difficult to design and synthesize, because the allosteric sites they bind to are often less well-defined than the orthosteric sites. Despite these challenges, research into PAMs is ongoing, and they represent an exciting area of drug discovery.

‎